Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Acetate

FDA-approved product (injectable, injection), marketed as Carmol Hc, Cortef Acetate, Cortifoam and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Inflammation
  • Pruritus
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Hydrocortisone Acetate reaches ≥40% AI-predicted activity against MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

    NCT02918409 · start 2016-08-26

    Registered record
    Registry ID
    NCT02918409
    Conditions
    Cystic Fibrosis
    Interventions
    Colistin; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08-26
    Completion
    2021-11-22
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionColistin; Tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

    NCT02452047 · start 2015-08-21

    Registered record
    Registry ID
    NCT02452047
    Conditions
    Bacterial Infections
    Interventions
    Imipenem+Cilastatin/Relebactam; Colistimethate sodium (CMS); Imipenem+Cilastatin; Placebo to CMS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08-21
    Completion
    2017-09-18
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionImipenem+Cilastatin/Relebactam; Colistimethate sodium (CMS); Imipenem+Cilastatin; Placebo to CMS
    PhasePhase 3
    Registry statusCompleted

  • Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection

    NCT02482961 · start 2015-05

    Registered record
    Registry ID
    NCT02482961
    Conditions
    Acinetobacter Infections
    Interventions
    colistimethate sodium
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05
    Completion
    2018-04-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Infections
    Interventioncolistimethate sodium
    PhaseNot recorded
    Registry statusCompleted

  • Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria

    NCT02134106 · start 2015-01

    Registered record
    Registry ID
    NCT02134106
    Conditions
    Bacteremia; Healthcare-associated Pneumonia; Ventilator-associated Pneumonia
    Interventions
    Polymyxin B; Polymyxin B + Doripenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2015-01
    Completion
    2015-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia; Healthcare-associated Pneumonia; Ventilator-associated Pneumonia
    InterventionPolymyxin B; Polymyxin B + Doripenem
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

    NCT01970371 · start 2014-09-16

    Registered record
    Registry ID
    NCT01970371
    Conditions
    Bloodstream Infections (BSI) Due to CRE; Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE; Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE; Complicated Urinary Tract Infection (cUTI) Due to CRE; Acute Pyelonephritis (AP) Due to CRE
    Interventions
    plazomicin; colistin; meropenem; tigecycline; antibiotic of Investigator's choice
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09-16
    Completion
    2016-09-15
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBloodstream Infections (BSI) Due to CRE; Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE; Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE; Complicated Urinary Tract Infection (cUTI) Due to CRE +1 more
    Interventionplazomicin; colistin; meropenem; tigecycline +1 more
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients

    NCT02117986 · start 2014-04

    Registered record
    Registry ID
    NCT02117986
    Conditions
    Gram Negative Bacterial Infections
    Interventions
    colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-04
    Completion
    2018-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram Negative Bacterial Infections
    Interventioncolistin
    PhasePhase 4
    Registry statusUnknown

  • Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)

    NCT01894347 · start 2013-09

    Registered record
    Registry ID
    NCT01894347
    Conditions
    Infection Resistant to Multiple Drugs
    Interventions
    TDM, Monitoring of Neuro-and Nephropathology
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Resistant to Multiple Drugs
    InterventionTDM, Monitoring of Neuro-and Nephropathology
    PhaseNot recorded
    Registry statusCompleted

  • Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired Infections

    NCT01798537 · start 2013-06

    Registered record
    Registry ID
    NCT01798537
    Conditions
    Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
    Interventions
    Neomycin Colistin Nystatin Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2015-07
    Enrolment
    2,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
    InterventionNeomycin Colistin Nystatin Vancomycin
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis

    NCT02556190 · start 2013-06

    Registered record
    Registry ID
    NCT02556190
    Conditions
    Infection Due to Resistant Bacteria; Acute Kidney Injury
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to Resistant Bacteria; Acute Kidney Injury
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem

    NCT01732250 · start 2013-03

    Registered record
    Registry ID
    NCT01732250
    Conditions
    Gram-Negative Bacterial Infections
    Interventions
    Colistin; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-03
    Completion
    2017-02-28
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Negative Bacterial Infections
    InterventionColistin; Meropenem
    PhasePhase 4
    Registry statusCompleted

  • Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?

    NCT01740947 · start 2013-01

    Registered record
    Registry ID
    NCT01740947
    Conditions
    Colorectal Cancer
    Interventions
    Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2017-03
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSelective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
    PhasePhase 4
    Registry statusTerminated

  • Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity

    NCT01501968 · start 2012-01

    Registered record
    Registry ID
    NCT01501968
    Conditions
    Drug Safety
    Interventions
    Colistin; Colistin + Ascorbic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-01
    Completion
    2013-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Safety
    InterventionColistin; Colistin + Ascorbic acid
    PhasePhase 3
    Registry statusUnknown

  • Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin

    NCT01845246 · start 2012-01

    Registered record
    Registry ID
    NCT01845246
    Conditions
    Multidrug Resistant Gram Negative Bacterial Infections
    Interventions
    Prospective TDM Arm of colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2015-08
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Gram Negative Bacterial Infections
    InterventionProspective TDM Arm of colistin
    PhaseNot applicable
    Registry statusCompleted

  • Renal Impairment Associated With Colistin Levels

    NCT01023087 · start 2009-12

    Registered record
    Registry ID
    NCT01023087
    Conditions
    Sepsis
    Interventions
    Polymyxin E (Colistin); Non-nephrotoxic antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionPolymyxin E (Colistin); Non-nephrotoxic antibiotics
    PhaseNot recorded
    Registry statusCompleted

  • Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

    NCT01035853 · start 2009-12

    Registered record
    Registry ID
    NCT01035853
    Conditions
    Cystic Fibrosis; Pseudomonas Aeruginosa
    Interventions
    Colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-12
    Completion
    2012-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pseudomonas Aeruginosa
    InterventionColistin
    PhasePhase 2
    Registry statusCompleted